Viracta Therapeutics, Inc. Profile Avatar - Palmy Investing

Viracta Therapeutics, Inc.

Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase…

Biotechnology
US, Cardiff-by-the-Sea [HQ]
Growth Rates · Payout · Yield

Dividends Over Time

  • Records
  • Forecasts [Soon]
Growth Rates
% YoY
% 3Yr
% 5Yr
% 10Yr
Key Metrics
- -% TTM Yield
- - Average Days Gap
Series
% - - Yield
0.00% Payout Ratio
Cash Amount Pay Date
Cash Amount Pay Date
End of VIRX's Analysis
CIK: 1061027 CUSIP: 92765F108 ISIN: US92765F1084 LEI: - UEI: -
Secondary Listings
VIRX has no secondary listings inside our databases.